279 related articles for article (PubMed ID: 27546620)
1. LKB1 inhibits HPV-associated cancer progression by targeting cellular metabolism.
Zeng Q; Chen J; Li Y; Werle KD; Zhao RX; Quan CS; Wang YS; Zhai YX; Wang JW; Youssef M; Cui R; Liang J; Genovese N; Chow LT; Li YL; Xu ZX
Oncogene; 2017 Mar; 36(9):1245-1255. PubMed ID: 27546620
[TBL] [Abstract][Full Text] [Related]
2. HPV E6/E7 promotes aerobic glycolysis in cervical cancer by regulating IGF2BP2 to stabilize m
Hu C; Liu T; Han C; Xuan Y; Jiang D; Sun Y; Zhang X; Zhang W; Xu Y; Liu Y; Pan J; Wang J; Fan J; Che Y; Huang Y; Zhang J; Ding J; Yang S; Yang K
Int J Biol Sci; 2022; 18(2):507-521. PubMed ID: 35002506
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus 16 (HPV 16) E6 but not E7 inhibits the antitumor activity of LKB1 in lung cancer cells by downregulating the expression of KIF7.
Hu Y; Wu MZ; Gu NJ; Xu HT; Li QC; Wu GP
Thorac Cancer; 2020 Nov; 11(11):3175-3180. PubMed ID: 32945133
[TBL] [Abstract][Full Text] [Related]
4. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
5. Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer.
Munagala R; Aqil F; Jeyabalan J; Gupta RC
Cancer Lett; 2015 Jan; 356(2 Pt B):536-46. PubMed ID: 25304375
[TBL] [Abstract][Full Text] [Related]
6. miR-106a Regulates Cell Proliferation and Autophagy by Targeting LKB1 in HPV-16-Associated Cervical Cancer.
Cui X; Wang X; Zhou X; Jia J; Chen H; Zhao W
Mol Cancer Res; 2020 Aug; 18(8):1129-1141. PubMed ID: 32345599
[TBL] [Abstract][Full Text] [Related]
7. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.
Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y
Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046
[TBL] [Abstract][Full Text] [Related]
8. Assessment of human papillomavirus E6/E7 oncogene expression as cervical disease biomarker.
Fontecha N; Basaras M; Hernáez S; Andía D; Cisterna R
BMC Cancer; 2016 Nov; 16(1):852. PubMed ID: 27816058
[TBL] [Abstract][Full Text] [Related]
9. Honeybee venom possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer cell line.
Kim YW; Chaturvedi PK; Chun SN; Lee YG; Ahn WS
Oncol Rep; 2015 Apr; 33(4):1675-82. PubMed ID: 25633640
[TBL] [Abstract][Full Text] [Related]
10. N6-methyladenosine methylation on FSCN1 mediated by METTL14/IGF2BP3 contributes to human papillomavirus type 16-infected cervical squamous cell carcinoma.
Tian Q; Huang J; Zhang Q; Zhao J
Clin Exp Pharmacol Physiol; 2024 Jun; 51(6):e13864. PubMed ID: 38679464
[TBL] [Abstract][Full Text] [Related]
11. HPV-16 E6/E7 promotes cell migration and invasion in cervical cancer via regulating cadherin switch in vitro and in vivo.
Hu D; Zhou J; Wang F; Shi H; Li Y; Li B
Arch Gynecol Obstet; 2015 Dec; 292(6):1345-54. PubMed ID: 26093522
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus E7 binds Oct4 and regulates its activity in HPV-associated cervical cancers.
Panayiotou T; Michael S; Zaravinos A; Demirag E; Achilleos C; Strati K
PLoS Pathog; 2020 Apr; 16(4):e1008468. PubMed ID: 32298395
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16.
Woodworth CD; Diefendorf LP; Jette DF; Mohammed A; Moses MA; Searleman SA; Stevens DA; Wilton KM; Mondal S
Virology; 2011 Dec; 421(1):19-27. PubMed ID: 21982220
[TBL] [Abstract][Full Text] [Related]
14. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16.
Hasan UA; Bates E; Takeshita F; Biliato A; Accardi R; Bouvard V; Mansour M; Vincent I; Gissmann L; Iftner T; Sideri M; Stubenrauch F; Tommasino M
J Immunol; 2007 Mar; 178(5):3186-97. PubMed ID: 17312167
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus oncoproteins differentially modulate epithelial-mesenchymal transition in 5-FU-resistant cervical cancer cells.
Vishnoi K; Mahata S; Tyagi A; Pandey A; Verma G; Jadli M; Singh T; Singh SM; Bharti AC
Tumour Biol; 2016 Oct; 37(10):13137-13154. PubMed ID: 27449048
[TBL] [Abstract][Full Text] [Related]
16. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.
Ding W; Hu Z; Zhu D; Jiang X; Yu L; Wang X; Zhang C; Wang L; Ji T; Li K; He D; Xia X; Liu D; Zhou J; Ma D; Wang H
Clin Cancer Res; 2014 Dec; 20(24):6495-503. PubMed ID: 25336692
[TBL] [Abstract][Full Text] [Related]
17. Human Papillomavirus E6/E7 and Long Noncoding RNA TMPOP2 Mutually Upregulated Gene Expression in Cervical Cancer Cells.
He H; Liu X; Liu Y; Zhang M; Lai Y; Hao Y; Wang Q; Shi D; Wang N; Luo XG; Ma W; Zhang TC
J Virol; 2019 Apr; 93(8):. PubMed ID: 30728257
[TBL] [Abstract][Full Text] [Related]
18. GSK3β mediates the carcinogenic effect of HPV16 in cervical cancer.
Ma C; Zeng C; Jin L; Yang Y; Li P; Chen L; Wang J
Sci Rep; 2015 Nov; 5():16555. PubMed ID: 26560046
[TBL] [Abstract][Full Text] [Related]
19. HPV positive neuroendocrine cervical cancer cells are dependent on Myc but not E6/E7 viral oncogenes.
Yuan H; Krawczyk E; Blancato J; Albanese C; Zhou D; Wang N; Paul S; Alkhilaiwi F; Palechor-Ceron N; Dakic A; Fang S; Choudhary S; Hou TW; Zheng YL; Haddad BR; Usuda Y; Hartmann D; Symer D; Gillison M; Agarwal S; Wangsa D; Ried T; Liu X; Schlegel R
Sci Rep; 2017 Apr; 7():45617. PubMed ID: 28378747
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes.
Zhou J; Li B; Peng C; Wang F; Fu Z; Zhou C; Hong D; Ye F; Lü W; Xie X
Antiviral Res; 2013 May; 98(2):305-13. PubMed ID: 23523766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
